Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin | Zendy

F. J. Zemp | Zendy; X. Lun | Zendy; Brienne McKenzie | Zendy; Hongyuan Zhou | Zendy; Lori Maxwell | Zendy; Beichen Sun | Zendy; John J. Kelly | Zendy; O. Stechishin | Zendy; A. Luchman | Zendy; Sarah A. Weiss | Zendy; J. Gregory Cairncross | Zendy; Mark G. Hamilton | Zendy; B. A. Rabinovich | Zendy; Maryam Rahman | Zendy; Mohamed R. Mohamed | Zendy; Sherin Smallwood | Zendy; Donna L. Senger | Zendy; John C. Bell | Zendy; Grant McFadden | Zendy; Peter Forsyth | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin

Author(s) -

F. J. Zemp,

X. Lun,

Brienne McKenzie,

Hongyuan Zhou,

Lori Maxwell,

Beichen Sun,

John J. Kelly,

O. Stechishin,

A. Luchman,

Sarah A. Weiss,

J. Gregory Cairncross,

Mark G. Hamilton,

B. A. Rabinovich,

Maryam Rahman,

Mohamed R. Mohamed,

Sherin Smallwood,

Donna L. Senger,

John C. Bell,

Grant McFadden,

Peter Forsyth

Publication year - 2013

Publication title -

neuro-oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.005

H-Index - 125

eISSN - 1523-5866

pISSN - 1522-8517

DOI - 10.1093/neuonc/not035

Subject(s) - oncolytic virus , myxoma virus , in vivo , neurosphere , temozolomide , biology , virotherapy , cancer research , stem cell , in vitro , population , brain tumor , glioma , immunology , medicine , virus , pathology , microbiology and biotechnology , tumor cells , biochemistry , environmental health , adult stem cell , endothelial stem cell

Intratumoral heterogeneity in glioblastoma multiforme (GBM) poses a significant barrier to therapy in certain subpopulation such as the tumor-initiating cell population, being shown to be refractory to conventional therapies. Oncolytic virotherapy has the potential to target multiple compartments within the tumor and thus circumvent some of the barriers facing conventional therapies. In this study, we investigate the oncolytic potential of myxoma virus (MYXV) alone and in combination with rapamycin in vitro and in vivo using human brain tumor-initiating cells (BTICs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research